Perspective is advancing multiple clinical programs across a range of tumors, and is using its proprietary platform to generate a robust pipeline novel pre-IND assets.
| PROGRAM (TARGET) |
TARGET DISEASE | CANDIDATE EVALUATION | HUMAN CLINICAL IMAGING | PHASE 1/2 | REGISTRATION ENABLING STUDY | STATUS |
|---|---|---|---|---|---|---|
| VMT-α-NET (SSTR2) |
Neuroendocrine Tumors Other SSTR2 Expressing Tumors |
|
Cohort 2: Completed recruitment
Cohort 3: Recruited DLT cohort Under evaluation |
|||
| VMT01/02 (MC1R) |
Melanoma (MC1R Imaging & Therapy) |
|
Enrolling 3.0 mCi
Enrolling 3.0 mCi |
|||
| PSV359 (FAP-α) |
Multiple Solid Tumors | Enrolling 5.0 mCi | ||||
| Multiple programs in preclinical development | Multiple Solid Tumors | Under evaluation | ||||
| Pre-Targeting Platform | Multiple Solid Tumors | Under evaluation | ||||